CJC-1295 vs Teduglutide
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone Peptides
CJC-1295Recovery & Repair
Teduglutide- Summary
- CJC-1295 is a synthetic GHRH analog that stimulates the pituitary gland to produce and release growth hormone. The DAC (Drug Affinity Complex) version has a markedly extended half-life. The No DAC version (Modified GRF 1-29) preserves natural pulsatile GH release and is preferred in most protocols.
- Teduglutide is a GLP-2 (glucagon-like peptide-2) analog with enhanced stability. Unlike GLP-1, GLP-2 specifically acts on the intestinal epithelium to increase intestinal length, villus height, and absorption surface area. FDA-approved as Gattex for short bowel syndrome, it is also being investigated for IBD, leaky gut, and mucosal healing.
- Half-Life
- ~30 minutes (No DAC) / 6–8 days (with DAC)
- ~2 hours; once-daily dosing due to gut-specific residence
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 100 mcg
- 0.05 mg/kg/day
- Frequency
- Once daily, before bed
- Once daily
- Key Benefits
- Sustained increase in growth hormone levels
- Enhanced muscle growth and strength
- Improved fat metabolism and body composition
- Better recovery and tissue repair
- Increased bone density
- Enhanced immune function
- Improved skin quality and collagen production
- Synergistic GH release when combined with GHRPs like Ipamorelin
- Increases intestinal villus height and absorption surface area
- Reduces intestinal permeability (leaky gut)
- FDA-approved for short bowel syndrome
- Reduces parenteral nutrition dependence in SBS patients
- Promotes intestinal mucosal healing in IBD
- Increases tight junction proteins ZO-1 and occludin
- Side Effects
- Water retention / puffiness
- Carpal tunnel syndrome (with prolonged use)
- Injection site irritation
- Hunger increase (minor)
- +1 more
- Injection site reactions
- Abdominal pain and bloating
- Nausea
- Risk of intestinal polyp growth (requires colonoscopy surveillance)
- +1 more
- Stacks With
- —
- —